Among Parkinson’s disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials
Objective: Evaluate the effects of ADS-5102 (amantadine) extended release capsules on motor complications and functional outcomes among patients experiencing both troublesome dyskinesia and OFF (disruptive…Use in Clinical Practice of a Personalised and Long-term Monitoring Device for Parkinson´s Disease: STAT-ON
Objective: To analyze the opinion of different neurologists from Spain about the STAT-ON tool after using the device in a real clinical practice setting (RCPS).…Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study
Objective: Evaluate the efficacy of apomorphine (APO) infusion in reducing OFF time during the hours of pump use in PD patients with motor fluctuations inadequately…Laboratory Performance of the DopaFuse® Delivery System
Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…STAT-ON: a Wearable Inertial System to Objectively Evaluate Motor Symptoms in Parkinson’s Disease
Objective: We present a wearable inertial system for the evaluation of motor symptoms in Parkinson's Disease. Background: PD is the second neurodegenerative disease affecting to around…A Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s Disease Complicated By “OFF” Episodes
Objective: To assess the effect of apomorphine sublingual film (APL130277; APL) on the QT interval in patients with Parkinson’s disease (PD) and “OFF” episodes participating…Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa (LD)-Treated Patients with Parkinson’s Disease (PD)
Objective: To observe whether increasing the istradefylline dose from 20 to 40mg/day provides more patients with meaningful clinical responses. Background: Istradefylline, a well-tolerated selective adenosine…Does information from the Personal KinetiGraph™ (PKG) influence neurologists´ treatment decisions?
Objective: To evaluate if PKG data influences neurologists´ treatment decisions in routine clinical care of patients with Parkinson´s disease. Background: The PKG movement recording system is…A characterization of the ADL-level in daily life with Parkinson`s Disease based on objective measurements and subjective experiences.
Objective: 1. Test whether slow response to the medication and EMO-periods (Early Morning Off), affects the patient`s experience of being able to perform ADL-functions. 2.…Efficacy of Istradefylline, an A2A Receptor Antagonist, When Added to Levodopa (LD) and Other Medications for Parkinson’s Disease (PD)
Objective: To evaluate the clinical effect of istradefylline as adjunctive treatment to LD in PD patients with or without additional PD medications (meds). Background: Istradefylline,…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 26
- Next Page »